BioWorld MedTech

Dec. 18, 2012

Boston Scientific to study next-gen pacing leads

The first patient has been implanted with the Boston Scientific next generation Ingevity pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads, the company reported. Read More

Washington roundup: Obama says no to device tax delay, argues 'new customers'

International report: ConvaTec reports launching of its operations in India

Financings roundup: Angel Medical closes on aggregate $27.5M round

Agreements/contracts: Baylor Health Care, Scott & White combining systems

Deals roundup: Florida Blue to acquire Diagnostic Clinic in Largo

Court report: Orthofix resolves investigation of its bone growth business

People in the News

Product Briefs

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...